Program Guide – ASCO Meeting Program Guide

Asciminib is the newest kid on the block for treatment of CML. This abstract presents week 96 update of ASCEMBL, the study that compared asciminib to bosutinib and helped obtain FDA approval for the drug.

Read the full article here

Related Articles